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Abstract 
The mammalian target of rapamycin (mTOR), a cytoplasmic serine/threonine kinase, represents a key biologic “switch” 
modulating cell metabolisms in response to environmental signals and is now recognized as a central regulator of 
the immune system. There is an increasing body of evidence supporting the hypothesis that mTOR inhibitors exhibit 
several biological properties in addition to immunosuppression, including anti-neoplastic effects, cardio-protective 
activities, and an array of immunomodulatory actions facilitating the development of an operational graft tolerance. 
The biological mechanisms explaining how mTOR inhibition can enable a tolerogenic state are still largely unclear. 
The induction of transplant tolerance might at the same time decrease rejection rate and minimize immunosuppres-
sion-related side effects, leading to an improvement in long-term graft outcome. In this scenario, T cell immunoregu-
lation has been defined as the hallmark of peripheral tolerance. Two main immunologic cell populations have been 
reported to play a central role in this setting: regulatory T cells (Tregs) and dendritic cells (DCs). In this review we focus 
on mTOR inhibitors effects on Treg and DCs differentiation, activation, and function in the transplantation setting.
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Background
Allograft rejection is a complex array of events involving 
both cellular and humoral adaptive immune response. 
This process is primed by the recognition of non-self 
histocompatibility antigens expressed within the graft. 
Recipient T cells may recognize graft major histocompat-
ibility complex (MHC) antigen through two main routes. 
The direct pathway is characterized by the presentation 
of alloantigen to recipient T cells by donor antigen-pre-
senting cells (APC). The indirect pathway involves the 
presentation of MHC alloantigen to T cells by recipient 
APCs [1–3]. Rejection is triggered by the clonal expan-
sion and activation of a T cell population recognizing 
one or more immunodominant peptides derived from 
the hypervariable region of donor’s HLA molecules. T 
cells, that recognize epitopes of the same molecule or of 
another HLA antigen, become activated and contribute 
to the amplification and maintenance of the allograft spe-
cific immune reaction [1–3].
Although leukocyte populations, including B cells and 
T cells, dendritic cells (DCs) and endothelial cells (ECs) 
can contribute to the destruction of the graft, they can 
also promote a tolerogenic immune response supporting 
long-term graft survival [3]. Regulatory cells that prevent 
allograft rejection are specialized leukocyte populations, 
selected during their development to present regulatory 
functions, and acquiring a tolerogenic phenotype in the 
graft microenvironment or in the graft-draining lymph 
nodes [3]. Operational transplantation tolerance has 
been defined as a stable graft function without signs of 
rejection in the presence of a minimal immunosuppres-
sion [4].
The mammalian target of rapamycin (mTOR), a cyto-
plasmic serine/threonine kinase, represents a key bio-
logic “switch” modulating cell metabolisms in response to 
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regulator of the immune system. Indeed, mTOR is a cen-
tral node in the signaling pathways integrating several 
environmental cues in the immune microenvironment. 
Rapamycin or Sirolimus, the first mTOR inhibitor, born 
as an antibiotic, was found to present powerful immu-
nosuppressive effects. Rapamycin’s effects on mTOR 
depend on its ability to bind to the immunophilin 
FKBP12 [5], the same bound by the calcineurin inhibi-
tor (CNI) tacrolimus. However, unlike tacrolimus, rapa-
mycin does not influence calcineurin activity and, thus, 
does not interfere with T cell receptor-induced NF-AT 
nuclear translocation. Originally, the immunosuppressive 
properties of rapamycin were believed to be due to its 
ability to inhibit T cell proliferation. Indeed, mTOR acti-
vation induces the degradation of the cell cycle inhibitor 
p27 along with an increase in cyclin D3 expression [5, 6]. 
Several experimental models suggested that T cell anergy 
was the result of T cell receptor (TCR) engagement, in 
the absence of proliferation and that IL-2-induced cell 
proliferation could induced a reversal of T cell anergy [7]. 
Since rapamycin inhibits cell proliferation, it was hypoth-
esized that mTOR inhibitors’ immunosuppressive effects 
might be, at least partially, due to their ability to promote 
anergy. Rapamycin can, indeed, induce T cell anergy even 
in the presence of a valid co-stimulation signal [8]. Inter-
estingly, concomitant inhibition of calcineurin blocked 
rapamycin-induced anergy [8, 9]. This observation high-
lights the fact that although CNI are potent suppressors 
of T cell activation, they may also prevent T cell toler-
ance [10]. However, the inhibition of cell proliferation is 
not the only mechanism underlying rapamycin-induced 
anergy. Indeed, cell cycle arrest in G1 in the absence of 
mTOR inhibition did not induce anergy, while inducing T 
cell proliferation in the presence of rapamycin was unable 
to overcome anergy [8, 9]. On the basis of these observa-
tions it is conceivable that the modulation of several sig-
nals controlled by mTOR may influence the activity of the 
two main cell types involved in transplantation tolerance, 
regulatory T cells (Tregs) and DCs.
Tregs and mTOR inhibition
Different T cell populations with regulatory activity 
might contribute to prevention of allograft rejection, 
including naïve T cells, CD4+ T cells, CD8+ T cells, 
CD4− CD8– T cells [11]. Naïve T cells require antigen 
presentation and co-stimulation for complete activa-
tion. When TCR bind the antigen within the MHC in the 
absence of co-stimulation, T cells neither proliferate nor 
produce IL-2. In addition, they remain unresponsive on 
rechallenge with the same antigen becoming anergic [7].
CD4+CD25+ Tregs are constitutively present in every 
healthy subject and express high levels of forkhead box P3 
(FOXP3), a key transcription factor for the development 
and function of these cells establishing a pattern of 
Tregs-specific gene expression [12, 13]. In solid-organ 
transplant recipients, there is an inadequate number of 
Tregs to prevent allograft rejection, in particular when 
donor-specific memory T cells specific are present. The 
high frequency of alloantigen-reactive T cells compared 
with the relatively small number of Treg cells promote 
an unbalance in the immune repertoire of the recipient 
leading to allograft destruction. The balance between 
graft rejection and regulation can be modulated, either 
before or after transplantation, using strategies based on 
the inhibition of effector T cells and/or on the increase 
of frequency or functional activity of alloantigen-reactive 
Tregs [14]. Tregs express on their cell surface high lev-
els of CD25, CD122 and 132, the alpha, beta and gamma 
chain, respectively, of IL-2 [15]. Although Tregs do not 
secrete this cytokine, this high, constitutive IL-2 recep-
tor expression suggests a great sensitivity of Tregs to 
this cytokine for both their activation and survival. In 
fact, Tregs may consume IL-2 in the microenvironment 
reducing the availability of this cytokine to effector T 
cells, thus causing their apoptosis [15]. On the other 
hand, Tregs immunosuppressive effects were associated 
with their secretion of suppressive cytokines or recep-
tors, including transforming growth factor-beta (TGF-
β), IL-10, IL-35 and cytotoxic T lymphocyte antigen 4 
(CTLA-4). Indeed, IL-10 or CTLA-4 inhibition results in 
a significantly decreased protection of the graft by Tregs, 
suggesting that IL-10 and CTLA-4 represent key media-
tors for the regulatory effects of this cell type [15].
There are several types of human CD8+ suppressor T 
cells, mainly (i) CD8+ CD28− FOXP3+ T suppressor cells 
[16] (ii) IL-10-secreting CD8+ CD28− FOXP3− T suppres-
sor cells [17], (iii) CD8+ CD57+ T suppressor cells [18].
CD8+CD28– T cells, prevent T cell activation through 
direct cell contact either with effector T cells or with 
APCs [19]. This regulatory cell population expresses 
FOXP3 mRNA, uses a limited TCR repertoire and recog-
nizes peptides presented within class I MHC molecules 
[19, 20]. As reported by Korecka-Polak et al. this cellular 
subset does not express FOXP3 protein [21].
CD8+CD28− T cells inhibit the activation of CD4+ T 
cells causing a reduced expression of several co-stimula-
tory molecules, including CD40, CD80, and CD86 and the 
up-regulation of the inhibitory receptors ILT3 and ILT4 on 
APCs, rendering them tolerogenic [20, 22]. The interaction 
between DCs and CD8+CD28– T cells primes a cascade of 
events, which result in effector T cell unresponsiveness to 
alloantigens presented via both direct and indirect path-
ways and subsequent graft adaptation [20, 22].
Differentially, CD8+ CD28− FOXP3− T suppressor cells 
are non-antigen-specific and they do not express CD56 
and CD127 molecules. Additionally, they are anergic and 
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this condition cannot be overcome under mitogens [23]. 
In  vitro CD8+ CD28− FOXP3− T suppressor cells are 
generated from CD8+ CD28− T cells after stimulation 
with IL-2 and IL-10 without the need for TCR stimula-
tion [24]. They inhibit the APC activity of DCs, T-cell 
proliferation and cytotoxicity of cytotoxic T lymphocyte 
through the secretion of IL-10 [17, 23, 25].
CD8+ CD57+ T suppressor cells are commonly found 
in individuals with chronic immune activation and in 
clinical conditions characterized by functional immune 
deficiency, including human immunodeficiency virus 
(HIV) and cytomegalovirus (CMV) infection [26]. These 
cells are characterized by cytotoxic potential due to the 
high levels of granzymes and perforin [27], and produce 
the immunomodulatory cytokines IFN-ɣ and TNF-α 
[28].
Recently, a novel subset of regulatory CD4−CD8− dou-
ble-negative (DN) T cells was described. DN T cells have 
the same features of terminally differentiated effector 
memory T cells reexpressing CD45RA+ (TEMRA), but are 
CD27+CD28+ and do not express the transcription fac-
tor T-bet which is highly expressed in TEMRA cells [29].
DN T cells modulate immune responses mediated by 
effector CD4+ and CD8+ T cells and prevent allograft 
rejection [30]. These cells may exert their immunosup-
pressive effects through several mechanisms. They are 
able to kill T cells in an antigen-specific fashion through 
the activation of the CD95–CD95L pathway, they can 
induce DC apoptosis, they can acquire alloantigens from 
DCs by trogocytosis and they cause a significant reduc-
tion in CD80 and CD86 expression on DCs surface. Par-
ticularly, this process requires CTLA4 expression by DN 
Tregs, since CTLA4− DN T were totally unable to down-
regulate the costimulatory molecules on DCs surface 
[29].
It has been demonstrated that tolerogenic DCs induced 
IFN-γ expression in DN T cells leading to their accu-
mulation in the spleens of operationally tolerant rats. 
Noteworthy, IFN-γ blockade in this setting resulted in 
allograft rejection [31].
Interleukin-7, that plays an important role in the home-
ostasis of the T cell compartment, can decrease the sup-
pressive activity of DN T cells activating the Akt/mTOR 
pathway in human DN T cells. Interestingly, selective 
inhibition of Akt/mTOR signaling has an opposite effect 
to IL-7 and restores the functionality of DN T cells [32].
Tregs can develop via two different pathways. Natu-
rally occurring or Thymus-derived Tregs, known as 
CD4+CD25+FoxP3+ Tregs, are selected in the thymus 
and exert their actions in the periphery usually to sup-
press responses to self-antigens. On the other hand, 
naive T  cells meeting the antigen in the periphery in a 
tolerogenic microenvironment may differentiate into 
inducible Tregs (iTregs). The induction of Foxp3 expres-
sion, essential for maintenance of tolerogenic character-
istics of Treg, in CD4+CD25− T cells is induced by IL-2 
and TGF-β [33–38], together with a suboptimal stimula-
tion of TCR.
In particular in the gut-associated lymphoid tissues 
(GALT) functionally specialized intestinal DC that 
express the integrin CD103 can induce gut-homing 
receptors on naïve CD4+  T cells through a mechanism 
depending on TGF-β and retinoic acid [35, 39–41].
The best studied subset of iTregs is the Tr1 cells which, 
in contrast to FoxP3+Tregs, lack FoxP3 expression and 
any lineage-specification transcription factor. They mod-
ulate T cell functions secreting particularly high levels of 
IL-10 [42]. For this feature, Tr1 cells represent one of the 
main T-cell mediators of cytokine-dependent immune 
regulation in both mice and humans and, accordingly, 
Foxp3+Treg and Tr1 cells are considered two distinct 
subsets of Treg cells [42].
Several in  vivo and in  vitro observations suggest an 
impact of rapamycin on both Tregs’ populations. In 
murine models rapamycin, but not CNI, induces the pro-
liferation and the regulatory effects of naturally occur-
ring Tregs [43]. Battaglia et al. [44] reported that in vitro 
activation of CD4+ T cells, obtained by healthy subjects 
or type 1 diabetic patients, in the presence of an mTOR 
inhibitor induces the expansion of CD4+CD25+FoxP3-
Tregs, which, in turn, inhibit syngeneic and allogeneic 
CD4+ and CD8+ T cell proliferation. Interestingly, they 
demonstrated that rapamycin, unlike CNIs, inhibiting 
the proliferation of effector T cells, spares and induces 
the growth of circulating Tregs and these cells show the 
ability to be expanded preserving their suppressive activ-
ity. In addition, several studies suggested that rapamycin 
might also induce the development of Tregs in mixed 
lymphocyte cultures [45]. Interestingly, in this setting, 
Tregs were not generated through the expansion of natu-
rally occurring regulatory T cells, but by the induction of 
a regulatory phenotype in conventional CD4+ T cells.
Moreover rapamycin resulted in enhanced Foxp3 
expression at high dose of anti-CD3 and anti-CD28 stim-
ulation. This effect is dependent on endogenous TGF-β 
since significantly reduced frequencies of Foxp3-express-
ing CD4+ T cells were detected in the presence of anti-
TGF-β antibody [46].
Therefore, mTOR inhibition can both expand natu-
rally occurring Tregs and induce adaptive Tregs from 
conventional CD4+ T cells. In addition, it has been 
recently demonstrated that rapamycin can also increase 
Tregs donor-specific suppressive ability [47]. It should 
be considered that the inhibitory effects of rapamycin 
on cytokine expression and T-cell differentiation might 
be cell specific, thus favoring Tregs expansion over of 
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effector T cells differentiation. Thus, it is conceivable that 
CD25 signaling through mTOR is absolutely needed for 
effector T cells differentiation, whereas Tregs may use an 
“escape” signaling pathway. This hypothesis is supported 
by the observation that in the presence of IL-2, rapamy-
cin alone or combined with stimulation delivered by TCR 
and CD28 can foster the selective proliferation of natu-
rally occurring Tregs [48]. IL-2 administration to pediat-
ric patients with sarcoma during immune reconstitution 
significantly increased peripheral Tregs number com-
pared to patients not receiving the cytokine therapy [49]. 
Similarly, in vitro observations suggest that cyclosporine 
A, inhibiting NFAT translocation into the nucleus, sup-
press FOXP3 promoter activity and subsequently its gene 
and protein expression in T cells [50]. In accordance, 
Pascual et al. [51] demonstrated that after withdrawal of 
CNIs in renal transplant patients, a significantly increase 
of Tregs in peripheral blood could be observed in com-
parison with patients remaining with CNI, indirectly sug-
gesting the previously described limitation of CNIs to 
favor the expansion of Tregs.
The mTOR inhibitors have provided a new powerful 
immunosuppressants potentially able to replace CNIs in 
kidney transplantation. The exact unique immunosup-
pressive profile of Sirolimus in humans was investigated 
in  vivo by Brouard et  al. [52] by employing phenotypic 
analysis on peripheral blood mononuclear cells (PBMCs) 
harvested from stable kidney recipients under immu-
nosuppressive therapy with Sirolimus or CNIs, they 
demonstrated that Sirolimus-treated recipients have a 
larger population of CD4+CD25+Foxp3+ Treg cells than 
those under CNIs [52]. In the clinical setting, the main 
therapeutic approach for reaching a tolerogenic state 
has been mainly based on recipient T-cell depletion and 
then, the use of minimal post-transplant immunosup-
pression based on mTOR inhibitors [53, 54] as main-
tenance immunosuppressive drugs. In these studies, 
authors showed a significant increase in the total number 
of circulating Tregs until 2  years after transplantation, 
and most interestingly, these Tregs were responsible of 
the anti-donor hypo-responsiveness achieved in some 
patients as demonstrated by their anti-donor suppressive 
activity ex  vivo. Also, patients displaying donor-specific 
hypo-responsiveness showed a significantly high propor-
tion of Tregs within cellular graft infiltrates.
DCs and mTOR inhibition
The DCs have attracted much interest in the medical 
community during the last years due to their strategic 
role in immune response linking innate and acquired 
immune responses and in the induction of tolerance to 
self and non-self antigens. Their capacity to regulate 
T-cell responses reflects the ability to provide critical 
instructive signals mediated by several specific co-stimu-
latory molecules such as B7, tumor necrosis factor family 
members (OX40, CD40, CD70), and specific cytokines. 
Adequate activation of these receptors results in DCs 
“maturation,” enhancing their ability to activate effec-
tor CD4+ and CD8+ T cells. On the contrary, immature 
and “semi-immature” DCs populations, which lack ade-
quate T-cell stimulatory ability, can suppress peripheral 
Ag-specific immune responses through the induction of 
T-cell anergy and deletion. In alloimmunity, the ability of 
both immature donor and recipient-derived DCs to sup-
press alloantigen-specific immune responses and prolong 
graft survival has been demonstrated in animal models. 
Both “immature” and “mature” DCs has been shown 
to be able to initiate the expansion of Tregs. Therefore, 
T-cell responses could be viewed as the culmination of 
a DCs-driven expansion and induction of effector func-
tions of both regulatory and non-regulatory T cells. In 
fact, there are several studies showing the capacity of 
DCs to expand/induce Tregs [55–57]. Tissue-resident 
immature DC presenting low numbers of self peptide-
MHC complexes coupled with limited co-stimulatory 
molecules expression can convert conventional naïve T 
cells into Treg probably as a consequence of their pres-
entation of an antigen to T cells without concomitant 
costimulation of cytokines. Nevertheless mature DC may 
retain their tolerogenic function depending upon expo-
sure to different stimuli. Activation of immature DC in 
the presence of IL-10, for instance, limits up-regulation 
of co-stimulatory molecules, decreases secretion of pro-
inflammatory cytokines, and increases IL-10 production 
[58, 59] enhancing Treg differentiation [60, 61]. Like-
wise immature DCs exposed to TNFα or IFNɣ although 
acquire high levels of MHC and costimulatory molecules, 
induce preferentially Treg differentiation [60, 61].
Within recent years, a growing number of publications 
have demonstrated that several clinically established 
immunosuppressive drugs target not only the effec-
tor cells but modulate also key functions of DCs [56]. 
Knowledge about the specific pharmacological effects 
of immunosuppressive agents on DCs does not only 
provide novel insight into the biological mode of action 
but additionally allows the development of experimen-
tal and clinical protocols that promote the generation 
of tolerogenic antigen presenting cells. One key pre-
requisite, however, for DCs to exert immunoregula-
tory functions is the migration into lymphoid tissues, 
where they can interact intimately with lymphocytes 
[57]. Sordi et al. showed in vitro and in vivo data reveal-
ing that the immunosuppressive macrolide rapamycin 
increases surface expression of the chemokine receptor 
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CCR7 on human and mouse derived DCs and conse-
quently promotes DCs migration into lymphoid tissue 
[62]. In contrast, the authors did not find significant bio-
logical effects of CNIs cyclosporine and FK506 on DCs 
chemokine receptor expression and migration. Rapamy-
cin was the first clinically relevant immunosuppressant 
to be shown to inhibit antigen uptake by DCs in  vitro 
and in  vivo [63]. The study by Sordi et  al. [62] reveals 
unique immunomodulatory effects of this drug on the 
migratory behavior of DCs. The authors employed dif-
ferent animal models in order to confirm their in  vitro 
observations of CCR7 up-regulation by rapamycin-
exposed human monocyte-derived DCs. Moreover, it 
should be noted, that the in vitro experiments have been 
performed with clinically relevant concentrations of 
rapamycin (1–10  ng/ml). The in  vivo migration experi-
ments with murine bone marrow derived DCs exposed 
ex  vivo to rapamycin demonstrated increased numbers 
of DCs in the regional lymph nodes after 24  h when 
compared to controls. These observations were further 
confirmed in a fluorescein-isothiocyanate skin-painting 
model with mice receiving a single dose of rapamycin 
orally. The in  vitro experiments show that competition 
for rapamycin’s intracellular receptor FKBP12 with a 
molar excess of FK506 can prevent the CCR7 up-regu-
lation induced by rapamycin. Thus, CCR7 up-regulation 
is likely to be a drug-specific effect related to the inter-
action of rapamycin with its intracellular receptor. The 
authors suggested that inhibition of endogenous IL-10 
was at least partially responsible for the observed effects, 
since anti- IL-10 mAbs impaired rapamycin’s effect on 
CCR7 expression [62].
Taken together, these findings demonstrate for the first 
time that a potent immunosuppressive agent can pro-
mote the migration of professional antigen presenting 
cells into lymphoid tissue. This may sound contradic-
tory if we see DCs only as potent stimulators of adaptive 
immune responses [62]. In fact, it makes a lot of sense, 
since an increasing number of studies have demonstrated 
that so called semi mature DCs transport continuously 
self-antigens into the T cell areas of lymphoid tissue and 
are important inducers of Tregs [64]. Thus, rapamycin’s 
pro-migratory effect on DCs indicates that this agent 
may exhibit immunoregulatory potential. With respect 
to this conclusion it is interesting to note, that the Pitts-
burgh group [65] reported that rapamycin-treated, 
alloantigen-pulsed DCs induce antigen-specific regula-
tion and prolong experimental heart allograft survival. 
Taner et  al. demonstrated that rapamycin-exposed DCs 
could be loaded with donor cell lysates and that infusion 
of these DCs prior to experimental heart transplantation 
prolonged fully MHC mismatched murine heart allo-
graft survival [65]. Interestingly, this effect was enhanced 
by repeated infusion of the cells. Taking into account all 
these findings rapamycin not only keeps DCs moving, 
but reveals novel aspects of pharmacological immuno-
suppression. In fact, these drugs inhibit DCs maturation 
and thus, T-cell stimulatory capacity both in  vitro and 
in vivo at clinically relevant levels.
Recently, we focused our attention on the inhibitory 
receptors ILT3 (Ig-like transcript 3) and ILT4 (Ig-like 
transcript 4) that are crucial to the tolerogenic pheno-
type acquired by professional and non-professional APC, 
such as dendritic and endothelial cells, respectively. ILT3 
and ILT4 belong to the Ig superfamily and are selectively 
expressed by professional and nonprofessional antigen-
presenting cells, including monocytes, macrophages, 
DCs, and endothelial cells [66, 67]. Similar to other 
members of the Ig superfamily, ILT3 and ILT4 present 
extracellular Ig-like domains and a long cytoplasmic tail 
containing an ITIM-like motif, which recruits inhibi-
tory phosphatases and transduces negative signals. IL-10 
and/or interferon-alfa induce ILT3 and ILT4 expression 
in DCs and endothelial cells and promote their abil-
ity to inhibit the proliferation of allogeneic T cells [22]. 
We demonstrated that rapamycin induces an increase 
in circulating plasmacytoid DCs with a significant up-
regulation of ILT3 and ILT4 and a reduction of CD40 
expression on their cell surface. These changes were 
associated with an increase in circulating CD8+CD28−T 
cells and CD4+CD25+Foxp3+CTLA4+ Tregs and with a 
significant switch from a Th1 to a Th2 bias in circulat-
ing and graft-infiltrating T cells [68]. Besides a significant 
change in DCs phenotype, it is conceivable that rapamy-
cin may also influence the main DCs functions. Moreo-
ver, has been demonstrated that rapamycin attenuates 
the hypoxic immune-inflammatory response through 
inhibition of the Hypoxia-inducible factor 1α (HIF-1α) 
pathway thus, abrogating effector alloimmune responses 
[69]. In an interesting report [70], it has been shown that 
DCs generated in the presence of rapamycin are poor 
allostimulators and resistant to maturation after CD40 
ligation. Outstandingly, although their T-cell allostimu-
latory ability was markedly impaired, rapamycin-DCs 
skew the balance of FoxP3-Tregs relative to T effectors, 
by maintaining the ability to stimulate Treg similar to 
control DCs. Moreover, when a single infusion of recip-
ient-derived, alloantigen-pulsed rapamycin-treated-DCs, 
combined with a short course of minimally effective 
rapamycin was performed, indefinite organ graft sur-
vival could be observed and it was associated with graft 
infiltration by Treg and the absence of transplant vascu-
lopathy [70]. Therefore, it seems that mTOR inhibitors 
may actively play a role in DCs to allow Treg activation 
while minimizing effector T-cell activation, thus favoring 
a tolerogenic state (Fig. 1).
Page 6 of 9Stallone et al. J Transl Med  (2016) 14:152 
Myeloid derived suppressor cells (MDSC) and mTOR 
inhibition
MDSC are a group of myeloid cells comprised of pre-
cursors of macrophages, dendritic cells, granulocytes 
and myeloid cells at early stage of differentiation with 
immune suppressive activity [71, 72].
MDSC can be divided in two groups, monocytic and 
granulocytic, based on phenotypic and functional fea-
tures [73]. Both groups express high levels of CD11b, 
CD33 and MHC class I, and low or absent expression 
of MHC class II molecules [74]. Conversely, they can be 
easily differentiated according to the expression of Ly6C 
(high in monocytic and medium in granulocytic MDSC) 
and CD14 (present only in monocytic MDSC).
These cells regulate immune response in cancer [71, 
75, 76], bacterial/parasitic infections, acute or chronic 
inflammation, traumatic stress, autoimmune disease 
and transplantation [77–81] by an intricate biologi-
cal machinery. In particular, MDSCs, expressing high 
levels of both arginase 1 and inducible nitric oxide syn-
thase (iNOS), may determine a significant depletion of 
l-Arginine in the microenvironment with a consequent 
decrease of the T cell proliferative capacity [82]. Moreo-
ver, NO released by iNOS suppresses T-cell function by 
the inhibition of JAK3, STAT5 and MHC class II [83–85]. 
Then, because of the depletion of arginine, iNOS may 
preferentially produce superoxide that, together with 
NO, generate peroxynitrite resulting in a nitration of 
TCR and impairment of T cell peptide/MHC interaction 
[86]. Other mechanisms proposed involve heme oxyge-
nase-1 (HO-1), TGF-β and indoleamine 2,3-dioxygenase 
(IDO) [87–89].
The influence of mTOR inhibition on MDSCs prolifera-
tion/function has been recently elucidated by Wu et  al. 
[90] in alloskin-grafted and tumour-bearing mouse mod-
els. In both models, mTOR inhibition (by rapamycin or 
mTOR KO) decreased percentages and number of mono-
cytic MDSCs and reduced immunosuppressive activity. 
The latter effect seemed to be due to the mTOR-I-related 
inhibition of iNOS and arginase activities. Contrarily, 
none of these effects was seen in granulocytic MDSCs.
Rapamycin, then, was also able to decrease mono-
cytic MDSC differentiation from myeloid progenitors by 
blocking the glycolysis, an essential pathway involved in 
MDSCs differentiation.
Summary
mTOR inhibitors and tolerance induction
The exact biological mechanisms underlying mTOR 
inhibitors tolerogenic effects are still largely unclear. 
Indeed, these immunosuppressive agents may modulate 
an array of signaling pathways. The potential molecular 
mechanisms have been mostly studied in animal models, 
although some relevant insights have been also reported 
in humans. The presence of T-cell immunoregulation 
has been defined to be the hallmark of peripheral allo-
graft tolerance. Two main immunologic cellular popu-
lations have been described to play a key role in this 
setting: CD4-Tregs and DCs. In fact, several reports have 
shown that the presence of activated CD4-Tregs play a 
critical role in controlling undesired immune responses 
to self and non-self-antigens, to prevent autoimmune 
diseases and to achieve peripheral allograft tolerance 
[91, 92]. Likewise, although professional antigen-pre-
senting DCs are known to be key initiators of effector 
alloimmune responses after transplantation, they have 
proved to be able to modulate alloimmune responses 
inducing antigen specific Tregs or directly suppress-
ing peripheral antigen-specific alloimmune responses 
through the induction of T-cell anergy and deletion [91, 
92]. Outstandingly, mTOR inhibitors have been shown 
to modulate the activities of these two particular cellular 
populations.
Conclusions
Rapamycin, a macrolide antibiotic produced by Strepto-
myces hygroscopicus, is an effective immunosuppressive 
drug used to prevent allograft rejection [5]. Similarly to 
the immunosuppressants FK506 and cyclosporine A 
(CsA), rapamycin exerts its effects binding to cyclophi-
lin. However, unlike FK506 and CsA, rapamycin does not 
inhibit T-cell receptor (TCR)–induced calcineurin activ-
ity. Rather, the rapamycin-FKBP12 complex inhibits the 
serine/threonine protein kinase mTOR, the activation 
of which is required for protein synthesis and cell cycle 
progression. Rapamycin blocks signaling in response 
to cytokines/growth factors, whereas FK506 and CsA 
exert their inhibitory effects blocking TCR-induced acti-
vation [5]. Consistent with this mechanism of action, it 
has been shown that rapamycin blocks T-cell-cycle pro-
gression from G1 to S phase after activation, promotes 
TCR-induced T-cell anergy even in the presence of co-
stimulation, and allows induction of operational toler-
ance. Additionally, it has been shown that mTOR takes 
part in several signalling pathways potentially involved in 
oncogenesis [93].
The great success achieved in organ transplanta-
tion in the 1990s drove investigators to look for refine-
ments in immunosuppression. This success was based 
on the excellent acute rejection prophylaxis provided 
by the CNIs. However, long-term allograft survival has 
been shown to be limited in the last decade, without the 
improvement that would have been expected [94]. In 
fact, among the main reasons, the chronic nephrotoxic 
effect of CNIs, leading to allograft scarring, induce the 
transplant community to seek for new non-nephrotoxic 
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immunosuppressive drugs such as mTOR inhibitors. 
Nevertheless, after 10 years of clinical experience mTOR 
inhibitors are still far to be positioned as a first-line 
immunosuppression in organ transplantation. Unex-
pectedly, CNIs are still considered as the cornerstone of 
immunosuppression. Indeed, there are several reasons 
for justifying this failure of mTOR inhibitors, including 
an increase in surgical and wound-healing complications, 
deferred recovery from delayed graft function in renal 
transplantation, the limits in anti-rejection effects in the 
presence of effector memory T cells, the association with 
post-transplant proteinuria and new onset diabetes after 
transplant (NODAT). However, there is increasing body 
of evidence supporting that more than playing an immu-
nosuppressive role, mTOR inhibitors display several, 
relevant biological properties including anti-neoplastic 
activity, cardiovascular protective actions, and specific 
immunomodulatory effects that might facilitate the 
achievement of operational allograft tolerance. Impor-
tantly, transplant tolerance is expected to reduce rejec-
tion while minimizing immunosuppressive side effects, 
potentially leading to a significant improvement of out-
come in the long term. In this setting, mTOR inhibi-
tors through different biological mechanisms have been 
shown to play a key role favoring this immune privilege 
state both in animal models and in humans.
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